Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2014	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
2014	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	14-12-09	RE
Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	14-12-09	RE
Merck : to take on superbugs with Cubist Pharma buy	14-12-09	RE
AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	14-12-08	RE
Apple : S&P 500 posts worst day since Oct; energy shares sink	14-12-08	RE
Cubist Pharmaceuticals : options unusually active before Merck deal	14-12-08	RE
Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	14-12-05	RE
Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	13-05-20	RE

Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	15-01-13	BU
Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	14-12-19	BU
Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.	14-12-09	PR
Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation	14-12-08	BU
Cubist Pharmaceuticals : European Antibiotic Awareness Day Highlights Need for Urgent Action	14-11-17	PU

Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen	14-12-21
Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées	14-12-20
Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars	14-12-08
Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète	14-12-08
Isetan Mitsukoshi : Les valeurs à suivre sur les marchés américains	14-12-08

Managers	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	96-12-31

Members of the board	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	70	06-08-31
Kenneth J. Martin BRD	Director/Board Member	70	13-09-24

Sector

	1st Jan change	Capi.
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.86B
BIOGEN INC.	-21.76%	29.36B
UCB	+58.56%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	17.31B
INCYTE CORPORATION	-18.49%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.31B